- Home
- / Compass Therapeutics
Compass Therapeutics
Stock Price
$1.7
2024-10-29
Market Capitalization
$233.9 M
2024-10-29
Revenue
$850 K
FY, 2024
Compass Therapeutics Summary
Company Summary
- Overview
- Compass Therapeutics is a therapeutic antibodies for cancer treatment and development company. The Company provides biophysical characterization of monoclonal antibodies, bispecifics, and other proteins in support of therapeutic antibody development programs.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- Cambridge, MA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Thomas J. Schuetz, Co-Founder, President of R&D, and Vice Chairman of the Board
Minori Rosales, Senior Vice President and Head of Clinical Development
Bing Gong, Vice President of Protein Sciences and Protein Analytics
LocationsView all
2 locations detected
Cambridge, MA HQ
United States
245 First St 3rd floor
Boston, MA
United States
80 Guest St #601
Compass Therapeutics Financials
Summary Financials
- Net income (Q1, 2026)
- ($18.3M)
- Cash (Q1, 2026)
- $55.2M
- EBIT (Q1, 2026)
- ($20.3M)
- Enterprise value
- $188.5M